10.1016/j.cell.2017.03.014 26 Prakash BabuN.PaolaM.Hamers AnoukA
The FDA has also approved Wegovy for adolescents aged 12 years and older who have obesity, defined as: a BMI at or above the 95th percentile for age and sex, based on CDC growth charts Must weigh at least 60 kg (132 lbs) Administered as a once-weekly subcutaneous injection Must be used in conjunction with a reduced-calorie diet and increased physical activity If an adolescent does not achieve at least a 5% reduction in BMI after 12 weeks on the 2.4 mg or maximum tolerated dose, treatment should be discontinued and re-evaluated In March 2024, the FDA approved Wegovy to reduce the risk of cardiovascular death, stroke, and heart attack in adults with cardiovascular disease and either obesity or overweight
They deliver the active ingredient through the skin layers to enter the bloodstream which can potentially work throughout the body
Integrated with the Noom Med app, it offered users expert clinical guidance throughout their journey
If a dose is missed, skip the missed dose and take the next dose the following day
Conclusion Tirzepatide offers a fresh, effective approach to weight loss and metabolic health